[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR035541A1 - Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio - Google Patents

Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio

Info

Publication number
AR035541A1
AR035541A1 ARP010105259A ARP010105259A AR035541A1 AR 035541 A1 AR035541 A1 AR 035541A1 AR P010105259 A ARP010105259 A AR P010105259A AR P010105259 A ARP010105259 A AR P010105259A AR 035541 A1 AR035541 A1 AR 035541A1
Authority
AR
Argentina
Prior art keywords
iop
combination
pio
intraocular pressure
need
Prior art date
Application number
ARP010105259A
Other languages
English (en)
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22937766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR035541(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of AR035541A1 publication Critical patent/AR035541A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Método de tratamiento para pacientes que sufren de glaucoma severo y para el tratamiento de individuos que necesitan una gran reducción de la presión intraocular (PIO) que comprende la administración simultánea de una combinación de agentes redustores de la PIO en el ojo. Uso de dos o varios agentes combinados junto con la capacidad para reducir la presión intraocular en una terapia con una mayor eficacia para tratar glaucoma avanzado en pacientes que padecen de deterioros detectables de la visión, cuando dichos agentes se administran simultáneamente. El uso combinado también presenta ventajas para el tratamiento de individuos que necesitan una gran reducción de la PIO, tal como los que están expuestos a factores de riesgo que los vuelve susceptibles a deterioros visuales. Preferentemente, se usa una combinación de reductores de la PIO que tiene diferentes acciones fisiológicas. Una combinación adecuada sería un agente que incremente el flujo del humor acuoso y un agente reductor de la formación de humor acuoso. Son de particular utilidad las prostaglandinas o los derivados de prostglandinas que tienen capacidad para reducir la PIO en combinación con uno o varios agentesreductores de la PIO que tengan otra acción fisiológica. Dichas prostglandinas se pueden seleccionar entre análogos y derivados de prostaglandina F2a (PGF2a). Son de especial utilidad aquellos derivados PGF2a que tienen un sustituyente con forma de anillo en el extremo terminal de la cadena omega de la estructura de prostaglandina F2a, tal como 13,14-dihidro-17-fenil-18,19,20-trinor-prostglandina-F2a-isopropiléster (latanoprost), 16-(meta-triflurometil)-fenoxi-17,18,19,20-tetranor-prostglandina-F2a-isopropiléster (travaprost) y compuesto similares. También es de utilidad el análogo del metabolito PGF2a, unoprostona de isopropilo.
ARP010105259A 2000-11-13 2001-11-09 Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio AR035541A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24812300P 2000-11-13 2000-11-13

Publications (1)

Publication Number Publication Date
AR035541A1 true AR035541A1 (es) 2004-06-16

Family

ID=22937766

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105259A AR035541A1 (es) 2000-11-13 2001-11-09 Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio

Country Status (17)

Country Link
US (1) US20030018079A1 (es)
EP (1) EP1333837A1 (es)
JP (1) JP2004513148A (es)
KR (1) KR20030068150A (es)
CN (1) CN1233324C (es)
AR (1) AR035541A1 (es)
AU (1) AU2002215277A1 (es)
BR (1) BR0115208A (es)
CA (1) CA2426049A1 (es)
EA (1) EA200300560A1 (es)
HU (1) HUP0400548A3 (es)
MX (1) MXPA03004183A (es)
NO (1) NO20032122L (es)
NZ (1) NZ525817A (es)
PL (1) PL362855A1 (es)
WO (1) WO2002038158A1 (es)
ZA (1) ZA200303771B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
DK2261369T3 (da) * 2002-03-13 2014-07-28 Genomic Health Inc Genekspressionsprofilering i biopsier af tumorvæv
AU2003222049B2 (en) * 2002-03-21 2007-05-31 Cayman Chemical Company, Incorporated Prostaglandin F2 alpha analogs in combination with antimicrobials for treating glaucoma
US20050245509A1 (en) 2002-08-29 2005-11-03 Santen Pharmacecutical Co., Ltd. Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
WO2005023258A1 (en) * 2003-09-05 2005-03-17 Novartis Ag Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
MXPA06007678A (es) 2004-01-05 2006-09-01 Nicox Sa Nitroxiderivados de prostaglandinas.
SI1759702T1 (sl) 2004-05-26 2009-06-30 Bayardo Arturo Jimenez Postopek pripravljanja oftalmiäśne raztopine latanoprosta in tako proizvedena raztopina
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US8629161B2 (en) 2005-06-21 2014-01-14 Kowa Co., Ltd. Preventive or remedy for glaucoma
US8193193B2 (en) 2005-07-12 2012-06-05 Kowa Co., Ltd. Agent for prevention or treatment of glaucoma
ITRM20080182A1 (it) 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
WO2010119305A1 (en) * 2009-04-14 2010-10-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of quaternary ammonium compounds in dissolving of latanoprost
CN102085175B (zh) * 2009-12-02 2013-01-30 沈阳兴齐眼药股份有限公司 一种眼用凝胶剂及其制备方法
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
CA2860453C (en) * 2011-01-24 2020-04-28 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
TW202126308A (zh) 2011-02-04 2021-07-16 日商興和股份有限公司 青光眼治療劑與高眼壓症治療劑
CN102389433A (zh) * 2011-11-04 2012-03-28 兆科药业(香港)有限公司 一种药物组合物及其复方制剂
TWI833535B (zh) 2017-12-21 2024-02-21 日商參天製藥股份有限公司 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥
CA3086445A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Omidenepag combination

Also Published As

Publication number Publication date
CN1233324C (zh) 2005-12-28
EA200300560A1 (ru) 2003-10-30
JP2004513148A (ja) 2004-04-30
US20030018079A1 (en) 2003-01-23
CA2426049A1 (en) 2002-05-16
EP1333837A1 (en) 2003-08-13
NO20032122D0 (no) 2003-05-12
MXPA03004183A (es) 2004-12-02
NZ525817A (en) 2005-03-24
BR0115208A (pt) 2003-10-07
AU2002215277A1 (en) 2002-05-21
HUP0400548A3 (en) 2007-05-29
ZA200303771B (en) 2004-05-17
CN1473046A (zh) 2004-02-04
NO20032122L (no) 2003-07-01
PL362855A1 (en) 2004-11-02
HUP0400548A2 (hu) 2004-06-28
KR20030068150A (ko) 2003-08-19
WO2002038158A8 (en) 2003-01-30
WO2002038158A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
AR035541A1 (es) Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
CA2293325C (en) 8-iso-prostaglandins for glaucoma therapy
Patel et al. Latanoprost: a review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension
Cortina et al. Docosahexaenoic acid, protectins and dry eye
TWI587857B (zh) 用於治療眼部發炎病症之酯類（二）
CA2845868C (en) Use of epa and dha in treating occular disorder
JP2009137971A (ja) 薬剤および薬剤キット
WO2009137085A3 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP5686819B2 (ja) 黄斑浮腫を処置するための医薬組成物
Camras et al. Initial clinical studies with prostaglandins and their analogues
KR20170086111A (ko) 안정화된 오메가-3 안과용 조성물
Greve et al. Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment
Pardines et al. Bilateral choroidal effusion after selective laser trabeculoplasty
Tamada et al. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma
Saito et al. Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma
CN106999452A (zh) 前列腺素类和一氧化氮供体的组合产品
ES2583127T3 (es) Aplicación transdérmica de prostaglandina E1 para el tratamiento de la isquemia ocular
BR0209601A (pt) Método para o tratamento da hipertensão ocular e do glaucoma
RU2633054C1 (ru) Фармацевтическая композиция в виде геля для лечения блефаритов
Lee et al. Travoprost-and Tafluprost-induced Changes in Intraocular Pressure and Ocular Pulse Amplitude
AR036276A1 (es) Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma
Michael et al. Macular heterotopia in proliferative diabetic retinopathy
Costea et al. Ocular complications due to intraoral local anesthesia: a case report
Lequeu et al. Long term IOP lowering efficacy of bimatoprost/timolol fixed combination: a 12 month prospective study
Gapunin et al. Results of the combined use of synthetic prostaglandins and nsaids to reduce intraocular pressure

Legal Events

Date Code Title Description
FC Refusal
FB Suspension of granting procedure